Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Keßler, Torsten [VerfasserIn]   i
 Müller-Tidow, Carsten [VerfasserIn]   i
Titel:Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
Verf.angabe:Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Saskia von Stillfried, Matthias Stelljes, Michele Pohlen, Georg Lenz, Anna Kirsch, Kerstin Vehring, Eva Wardelmann, Wolfgang Hartmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Müller-Tidow, Wolfgang E. Berdel
E-Jahr:2019
Jahr:21 March 2019
Umfang:9 S.
Fussnoten:Gesehen am 14.06.2019
Titel Quelle:Enthalten in: Annals of hematology
Ort Quelle:Berlin : Springer, 1955
Jahr Quelle:2019
Band/Heft Quelle:98(2019), 6, Seite 1393-1401
ISSN Quelle:1432-0584
Abstract:We evaluated pazopanib (800 mg orally QD) in patients not eligible for intensive treatment with relapsed/refractory AML or at initial diagnosis. Patients receiving pazopanib for > 14 days were analyzed for safety, tolerability, and efficacy. Co-primary endpoints were cumulative response rate and reduction of bone marrow microvessel density. Twenty patients (median age 76 years, range 52-86) were treated. Fifteen had relapsed/refractory and five had newly diagnosed AML. Median ECOG performance status was 1 (range 1-3). Four patients had adverse, 15 intermediate, and 1 patient favorable cytogenetic/molecular risk (ELN 2010 criteria). The safety profile of pazopanib was as reported. The most common adverse events of any grade were gastrointestinal. Two patients achieved PR (blast reduction > 50%), 14 stable disease (SD), and 4 progressive disease. Median PFS was 65 days (95% CI 29-105). After the end of the study, 1 CRi and 1 CRp occurred on demethylating agents, and 1 CR upon alloSCT. In these patients, SD and improved general condition on pazopanib allowed therapy escalation. Median OS for the overall study population was 191 days (95% CI 87-435) and 1-year survival was 35%. There was no significant change in microvessel density. Clinical trial information: NCT01361334.
DOI:doi:10.1007/s00277-019-03651-9
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00277-019-03651-9
 DOI: https://doi.org/10.1007/s00277-019-03651-9
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Acute myeloid leukemia
 AML
 Pazopanib
 Phase II study
K10plus-PPN:1667485679
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68398929   QR-Code
zum Seitenanfang